ArticleFrontiers in medicine2021
Kidney Function Is Not Related to Brain Amyloid Burden on PET Imaging in The 90+ Study Cohort.
Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Cognitive impairment in chronic kidney disease: mechanisms, clinical manifestations, and management strategies.Metabolic brain disease · 2025Review
- Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations.Neurology · 2025Observational
- Association between herpes simplex virus infection and Alzheimer's disease biomarkers: analysis within the MAPT trial.Scientific reports · 2025Article
- Cerebral perfusion and amyloidosis in the oldest-old.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Resilience to AD pathology in Top Cognitive Performers.Frontiers in aging neuroscience · 2024Article
- Association of impaired kidney function with dementia and brain pathologies: A community-based cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- New insights into cognitive decline in chronic kidney disease.Nature reviews. Nephrology · 2023Article
- Kidney Disease and Brain Health: Current Knowledge and Next Steps.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023Article
- Changes in Serum Cystatin C Levels and the Associations With Cognitive Function in Alzheimer's Disease Patients.Frontiers in aging neuroscience · 2021Article
- Changes in Alzheimer's disease blood biomarkers in kidney failure before and after kidney transplant.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Cognitive decline is common in chronic kidney disease (CKD). While the evidence of vascular cognitive impairment in this population is robust, the role of Alzheimer's pathology is unknown. We evaluated serum cystatin C-estimated glomerular filtration rate (eGFR), brain amyloid-β positron emission tomography (PET) imaging, and cognitive function in 166 participants from The 90+ Study. Mean age was 93 years (range 90-107) and 101 (61%) were women; 107 participants had normal cognitive status while 59 participants had cognitive impairment no dementia (CIND) or dementia. Mean ± standard deviation cystatin C was 1.59 ± 0.54 mg/L with eGFR 40.7 ± 18.7 ml/min/1.73m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.